Table 2.
Ongoing clinical trials of novel agents in patients with PTCL
| Agent | Targeting site | Phase | ClinicalTrial.gov ID |
|---|---|---|---|
| Endostar | Angiogenesis inhibitor | II | NCT02520219 |
| Selinexor | Selective inhibitor of nuclear export | II | NCT02314247 |
| Tipifarnib | Farnesyltransferase inhibitor | II | NCT02464228 |
| Darinaparsin | Organic arsenic compound | I | NCT01435863 |
| NCT01689220 | |||
| Ixazomib | Proteasome inhibitor | II | NCT02158975 |
| Denileukin diftitox | Interleukin fusion protein | II | NCT00050999 |
| NCT00051012 | |||
| Forodesine | PNP inhibitor | I/II | NCT01776411 |
| Ruxolitinib | JAK inhibitor | II | NCT01431209 |
| Temsirolimus | mTOR inhibitor | I | NCT01614197 |
| Carfilzomib | Proteasome inhibitor | I | NCT01336920 |
| Panobinostat | Pan-deacetylase inhibitor | II | NCT01261247 |
| Clofarabine | DNA synthesis inhibitor | I/II | NCT00644189 |
| MK2006 | AKT inhibitor | II | NCT01258998 |
| Sorafenib | Multikinase inhibitor | II | NCT00131937 |
| Alefacept | Immunosuppressive dimeric fusion protein | I | NCT00438802 |
| Pembrolizumab | PD-1 antibody | II | NCT02535247 |
PNP purine nucleoside phosphorylase, JAK Janus kinases, mTOR mammalian target of rapamycin, PD-1 programmed death-1